Fundraising Fox

Envisagenics

New York, US · Founded 2014 · Delaware corporation · 7 known investors

envisagenics.com ↗

Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases. The company combines RNA biology expertise with machine learning to advance precision medicines.

AI & Machine LearningBiotechMedical Devices

Founders & leadership

Envisagenics was founded in 2014 by Maria Pineda, PhD, Martin Akerman, PhD, Martin Akerman, Maria Luisa Pineda, and Maria Luisa Pineda, PhD..

MPMaria Pineda, PhD
Maria Pineda, PhDCEO & Co-founder
MAMartin Akerman, PhD
Martin Akerman, PhDCEO & Co-founder
MAMartin Akerman
Martin AkermanCo-founder
ML
Maria Luisa PinedaCo-founder
MLMaria Luisa Pineda, PhD.
Maria Luisa Pineda, PhD.inCEO, Cofounder

Investors · 7

Dynamk CapitalNew York
HAWKTAILSan Francisco
M12 (Microsoft's Venture Fund)Seattle · $100K – $10M
Madrona Venture GroupSeattle · $2M – $10M
Red Cell IncubationTysons
Dolby Family Venturesreported · 2 sourcesSan Francisco
Third Kind Venture CapitalreportedNew York · $50K – $5M

Funding

SEC filings, press & company announcements

$21.7M disclosed across 2 of 4 rounds · 2017–2024

  • Undisclosed amountSeries BJun 2024 · 2 sources
    Source ↗
▶$19.2MraisedOct 2021 · 24 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • ALAN S. ROEMERDirector
  • BRADLEY HARRISExecutive Officer
  • MARTIN AKERMANExecutive Officer, Director
  • GRANT VERSTANDINGDirector
  • MARIA LUISA PINEDAExecutive Officer, Director
Offering amount
$19.2M
Amount sold
$19.2M
Minimum investment
$1
First sale
Sep 2021
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$2.5MraisedOct 2017 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Martin AkermanExecutive Officer, Director, Promoter
  • Maria Luisa PinedaExecutive Officer, Director, Promoter
Offering amount
$2.5M
Amount sold
$2.5M
First sale
Mar 2017
Incorporated
Corporation, Delaware, 2014
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 3

by search overlap
Genomeweb17 shared keywordsGenomeWeb's Research Funding section publishes news coverage of research grants and government funding trends in genetics, genomics, and molecular diagnostics. It is an industry news publication serving researchers and organizations in the life sciences.
IQVIA10 shared keywordsIQVIA provides data, analytics, AI, and technology-driven services for life sciences and healthcare organizations, spanning clinical development, real world evidence generation, and commercial execution. It offers integrated solutions for clinical trials, regulatory and safety compliance, and market analytics, including agentic AI products for commercial and R&D teams.
Heligenics9 shared keywords

Companies competing with Envisagenics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 4 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase II2022$2.1M
National Institutes of Health (NIH)National Institutes of HealthPhase I2019$301.5K
National Institutes of Health (NIH)National Institutes of HealthPhase II2018$1.6M
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$225K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Envisagenics raises $25M Series B for gene therapies - Crain's New York Businesscrainsnewyork.com · Jun 2024Envisagenics Raises Series B Fundingfinsmes.com · Jun 2024Exclusive: Inspired by Spinraza, startup raises $25M for cancer drug targets created by alternative RNA splicingendpoints.news · Jun 2024Envisagenics Raises $2.25m in Seed Funding - FinSMEsfinsmes.com · Nov 2017

Frequently asked questions

What does Envisagenics do?
Envisagenics uses AI-driven analysis of RNA splicing to discover novel drug targets for immuno-oncology and neurodegenerative diseases. The company combines RNA biology expertise with machine learning to advance precision medicines.
Who founded Envisagenics?
Envisagenics was founded by Maria Pineda, PhD, Martin Akerman, PhD, Martin Akerman, Maria Luisa Pineda, Maria Luisa Pineda, PhD. in 2014.
Who are Envisagenics's investors?
Envisagenics's investors include Dynamk Capital, HAWKTAIL, M12 (Microsoft's Venture Fund), Madrona Venture Group, Red Cell Incubation, Dolby Family Ventures, Third Kind Venture Capital.
How much funding has Envisagenics raised?
Envisagenics has disclosed $21.7M raised across 2 of its 4 known rounds.
Where is Envisagenics headquartered?
Envisagenics is headquartered in New York, US.